Ibex Medical Analytics vs Paige (2026)
This pairing sets pathology's historic first against its most deployed second read, and the deciding facts changed recently. Paige produced the first FDA authorized AI pathology product, Paige Prostate through the De Novo pathway, and has since pursued foundation model work with a Breakthrough Device designation for pan cancer detection, but it was acquired by Tempus in August 2025 and is no longer an independent vendor. Ibex describes itself as the most widely deployed AI platform in pathology, its cleared prostate product works as a second read that flags cancers missed on initial assessment, a structure that avoids automation bias by running after the pathologist rather than before, and it holds the most complete set of published security and quality certifications in this index's pathology lane. If your failure mode is betting on where computational pathology is heading and Tempus ownership fits your stack, start with Paige. If your failure mode is deploying into routine practice today with attestations your security review will accept, start with Ibex. A Breakthrough designation is a development status, not a clearance.
- The oversight structure is the safety argument: the cleared prostate product runs as a second read after the pathologist, flagging small and rare cancers missed on initial assessment, which structurally avoids automation bias.
- Your security review is the gate: an unusually complete published certification set, graded A on this index's security axis, the standard the rest of the pathology lane is held to.
- Routine clinical deployment breadth: prostate, breast, and gastric solutions described as in routine clinical practice worldwide, with FDA 510(k) clearance on the prostate in vitro diagnostic.
- Regulatory history and pathway: the first FDA authorized AI based digital pathology product, cleared through De Novo, which established the pathway others now follow.
- Foundation model direction: pan cancer detection spanning common and rare variants across multiple tissue types, holding FDA Breakthrough Device designation, a development signal though not a clearance.
- Tempus alignment is a feature for you: as part of Tempus since August 2025, the pathology capability sits inside a broader indexed oncology platform, which suits buyers already in that ecosystem.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Ibex Medical Analytics and Paige are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Ibex Medical Analytics | Paige |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2016 | 2018 |
| Headquarters | Tel Aviv, Israel | New York, New York, United States |
| Website | ibex-ai.com | paige.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Ibex Medical Analytics its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Security Certifications and Trust Center. Set against Paige, Ibex Medical Analytics grades higher on several axes, including Autonomy and Oversight Model, AI Safety and PHI Stewardship and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Paige its top capability grade on AI Centrality and FDA and Regulatory Status. Set against Ibex Medical Analytics, Paige grades higher on AI Governance and Bias Disclosure and EHR and Interoperability Depth. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Ibex Medical Analytics or Paige?
On the axes where the AI Health Index separates them, Ibex Medical Analytics grades higher on several axes, including Autonomy and Oversight Model, AI Safety and PHI Stewardship and Security Certifications and Trust Center, and Paige grades higher on AI Governance and Bias Disclosure and EHR and Interoperability Depth. Ibex Medical Analytics leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Ibex Medical Analytics and Paige differ most?
The widest separation the AI Health Index records between Ibex Medical Analytics and Paige is on Autonomy and Oversight Model, where Ibex Medical Analytics grades A and Paige grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Ibex Medical Analytics and Paige grade the same?
The AI Health Index grades Ibex Medical Analytics and Paige the same on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Deployment claims for both vendors are vendor published, including Ibex's most widely deployed description. Paige was acquired by Tempus in August 2025 for a reported $81.25 million and is indexed under that ownership; buyers should establish contractual continuity terms, a question this index raises across recently acquired pathology platforms. Breakthrough Device designation is not FDA clearance and confers no marketing authorization. Neither vendor publishes pricing.